EP Patent

EP2327696A1 — Prolyl hydroxylase inhibitors and methods of use

Assigned to Akebia Therapeutics Inc · Expires 2011-06-01 · 15y expired

What this patent protects

The present invention relates to compounds having formula I and a medicament containing them

USPTO Abstract

The present invention relates to compounds having formula I and a medicament containing them

Drugs covered by this patent

vadadustat (VADADUSTAT)

Patent Metadata

Patent number: EP2327696A1
Jurisdiction: EP
Classification: —
Expires: 2011-06-01
Drug substance claim: No
Drug product claim: No
Assignee: Akebia Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.